Chen et al. (2019) used WGCNA, and identified the long non-coding RNA, LOC646762 as a potential biomarker for predicting the survival of adult AML patients, as well as for risk stratification. Similarly, Ye et al. (2019) identified cysteine-rich intestinal protein 1 (CRIP1) as a potential prognostic biomarker in AML patients using the WGCNA co-expression network analysis. This evidence concerns the gene CRIP1 and acute myeloid leukemia.